查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1868263

Dravet症候群市场按药物类别、最终用户、通路、给药途径和患者年龄组划分 - 全球预测 2025-2032

Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route Of Administration, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，Dravet 症候群市场规模将达到 14.5989 亿美元，复合年增长率为 8.97%。

关键市场统计数据
基准年 2024 7.3404亿美元
预计年份：2025年 8.8亿美元
预测年份 2032 1,459,890,000 美元
复合年增长率 (%) 8.97%

这是一份全面且具有临床依据的Dravet综合征概述，重点介绍了诊断技术的进展、治疗的复杂性以及不断变化的医疗保健服务需求。

Dravet症候群是一种罕见的严重癫痫性脑病变，发病于婴儿期，其特征是长期、难治性癫痫发作和进行性神经发育障碍。临床管理复杂且涉及多学科，需要神经内科、急诊科、癫痫专科中心和家庭看护者之间的密切协调。儘管近年来透过早期基因检测提高了诊断准确性，并且人们对该疾病的表型多样性认识不断提高，但许多患者仍然面临严重的癫痫发作负担和显着的合併症，导致医疗需求未得到满足。

确定临床、监管和数位因素的融合，这些融合将从根本上改变德拉韦综合征的治疗路径、治疗机会和相关人员的优先事项。

Dravet症候群的治疗模式正受到多种变革因素的影响而转变，这些因素正在重塑临床护理、研究重点和商业策略。在临床层面，早期基因诊断和以表型为基础的治疗选择使得更个人化的治疗方案成为可能，而日益成熟的癫痫专科网络则集中了专业知识，并改善了长期照护的协调性。同时，药理学的进步正在丰富治疗选择，并重新激发人们对靶向离子通道功能、GABA能调节和神经调节通路的不同药物类别的兴趣。

了解不断变化的美国关税政策对供应链、筹资策略以及治疗德拉韦综合征药物取得途径的累积营运和商业影响。

2025年，美国关税趋势为德拉韦综合征治疗领域的製造商、经销商和供应商的营运带来了新的复杂性。影响进口活性药物原料药、某些医疗设备和包装组件的关税增加了上游工程投入成本，促使许多企业重新评估其供应链的韧性。拥有全球製造地的公司被迫评估商品的总到岸成本，并考虑将关键生产过程流程转移到国内或近岸，以降低贸易政策波动带来的风险。

透过整合药物类别、临床环境、通路、给药途径和特定年龄层的临床需求等因素，进行深度细分，从而指南策略规划。

细分市场分析揭示了不同药物类别、终端使用者、分销管道、给药途径和患者群体在临床和商业性动态方面存在显着差异。在药物类别细分中，基于大麻素的药物持续受到关注，其治疗益处主要集中在大麻二酚 (CBD) 和四氢大麻酚 (THC) 这两种亚成分上。同时，包括Clobazam、Diazepam和曲普尼硫醇在内的 GABA 调节剂仍然是核心辅助性治疗。托吡酯和丙戊酸钠等钠通道阻断剂对某些类型的癫痫发作仍然有效，这些药物的相对安全性和耐受性会影响处方医生的选择和联合治疗策略。

区域临床和商业性洞察反映了美洲、欧洲、中东和非洲以及亚太地区的准入实践、监管差异和医疗保健基础设施。

区域趋势对德拉韦综合征治疗的临床实践、法规环境和商业性机会有显着影响。在美洲，相关人员受益于成熟的专科医疗网络、先进的基因诊断基础设施以及不断发展的支付模式，这些都提高了对具有临床和功能改善意义的证据的接受度。然而，医疗服务取得仍面临挑战，尤其是在农村和资源匮乏的社区，这些地区的癫痫专科中心稀缺，远端医疗的普及程度也因支付方政策而异。

策略企业格局分析揭示了大型製药企业、生物技术创新者、学术研究机构和服务供应商之间的整合能力将如何决定它们的竞争地位。

Dravet症候群的生态系统是一个由众多互补参与者组成的复杂体系，其中包括成熟的製药公司、专业生物技术公司、学术研究机构、契约製造生产商和专科药房。现有企业拥有后期研发和大规模生产能力，以及支援与复杂的支付方谈判和广泛分销网络的商业基础设施。专业生物技术公司则透过标靶作用机制和新型製剂提供创新，推动早期临床试验，并利用策略伙伴关係扩大治疗方法规模。

针对德拉韦综合征利害关係人的独特需求，针对产品开发、供应链优化和支付方参与，提出切实可行且影响深远的建议。

行业领导者应采取务实、以证据为导向的行动，将科学进步转化为永续的患者获益和商业性成功。首先，应优先与监管机构和支付方进行早期和持续的沟通，使证据生成与报销要求相符，并製定能够满足儿童安全性和有效性终点的适应性开发计划。其次，应投资于诊断基础设施和基因检测伙伴关係，以加速早期精准诊断，从而改善临床实验参加者的招募和真实世界治疗标靶的识别。

采用透明的混合方法调查方法，结合临床证据审查、专家访谈和案例研究分析，以得出可操作且检验的研究结果。

本分析的调查方法结合了严谨的证据综合和有针对性的相关利益者参与，以确保其相关性和可信度。主要资料来源包括对同行评审的临床文献、监管指导文件和临床试验註册资料的系统性回顾，以了解治疗机制、安全性特征和研究设计。次要资料来源包括公开的政策和支付方文件、技术白皮书和实践指南，以阐明准入途径和临床应用趋势。此外，也对神经科、癫痫学家、专科药剂师和卫生经济学专家进行了专家访谈，以检验解释性发现并提取文献中未必总是显而易见的实际操作考量。

前瞻性结论整合了临床进展、营运要务以及改善Dravet症候群患者照护和就医途径所需的协作策略。

总之，应对德拉韦症候群复杂的临床和商业性挑战需要诊断、治疗和医疗服务取得方面的协调努力。基因诊断技术的进步和治疗方法的多样化为改善癫痫控制和发育结果创造了新的机会，但要实现这些益处，需要严谨的循证策略、稳健的供应链以及与支付共用的价值认知。儘管医疗服务模式向远端医疗和以专家为中心的模式转变为扩大医疗服务取得铺平了道路，但仍存在一些差距，需要在地方和区域层面采取有针对性的干预措施。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大针对Dravet症候群患者SCN1A突变的基因治疗产品线
  • 大麻二酚製剂在Dravet症候群辅助癫痫治疗的应用日益广泛
  • 增加对精准医疗倡议的投入，以治疗儿童癫痫性脑病变
  • 在整合真实世界数据以评估Dravet症候群长期治疗效果方面取得进展
  • 新型反义寡核苷酸的出现，旨在调节缺陷钠通道基因表现。
  • 开发一种基于人工智慧的家用癫痫监测设备，可对德拉韦综合征进行即时干预。
  • 透过製药公司和生技公司之间的合作，加速罕见癫痫疾病的临床试验

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. Dravet症候群药物市场

  • 大麻素
    • CBD
    • THC
  • GABA调变器
    • Clobazam
    • Diazepam
    • 链戊硫醇
  • 钠通道阻断剂
    • 托吡酯
    • 丙戊酸

9. 按最终用户分類的德拉韦氏症候群市场

  • 居家照护
  • 医院
  • 癫痫专科中心

第十章 Dravet症候群市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科药房

第十一章 德拉韦氏症候群药物市场（依给药途径划分）

  • 注射
  • 鼻腔
  • 口服
  • 口腔黏膜给药
  • 经皮

第十二章：依患者年龄层分類的德拉韦症候群市场

  • 青春期
  • 成人
  • 儿童
  • 婴儿

第十三章 德拉韦氏症候群市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 德拉韦氏症候群市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国德拉韦氏症候群市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Jazz Pharmaceuticals plc
    • UCB SA
    • Marinus Pharmaceuticals, Inc.
    • Stoke Therapeutics, Inc.
    • Zogenix, Inc.
    • Biogen Inc.
    • Ionis Pharmaceuticals, Inc.
    • Xenon Pharmaceuticals Inc.
    • Ovid Therapeutics, Inc.
    • Zynerba Pharmaceuticals, Inc.
Product Code: MRR-4D00F1312C81

The Dravet Syndrome Market is projected to grow by USD 1,459.89 million at a CAGR of 8.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 734.04 million
Estimated Year [2025] USD 800.08 million
Forecast Year [2032] USD 1,459.89 million
CAGR (%) 8.97%

A comprehensive and clinically grounded introduction to Dravet syndrome emphasizing diagnostic advances, therapeutic complexity, and evolving care delivery imperatives

Dravet syndrome represents a rare, severe epileptic encephalopathy with onset in infancy, characterized by prolonged, treatment-resistant seizures and progressive neurodevelopmental impairment. Clinical management is complex and multidisciplinary, requiring careful coordination between neurology, emergency medicine, specialty epilepsy centers, and home-based caregivers. Recent years have seen advances in diagnostic precision through earlier genetic testing and improved recognition of the condition's phenotypic heterogeneity, yet many patients continue to experience high seizure burden and profound comorbidities that drive unmet clinical needs.

This introduction frames the landscape in terms of evolving therapeutic modalities, care delivery shifts, and commercial implications. It emphasizes the interplay between novel pharmacologic strategies targeting specific pathophysiologic mechanisms, supportive and rescue interventions for acute events, and the critical role of specialized care settings. The narrative also highlights how payer policies, distribution pathways, and patient age segmentation shape access and adherence. By situating Dravet syndrome within contemporary clinical practice and policy trends, the section primes stakeholders to evaluate opportunities across drug classes, routes of administration, and care delivery innovations while remaining attuned to the ethical and regulatory complexities that accompany treatments for pediatric populations.

Identifying the convergent clinical, regulatory, and digital forces that are fundamentally transforming treatment pathways, therapy access, and stakeholder priorities in Dravet syndrome

The landscape for Dravet syndrome is shifting along multiple transformative vectors that are reshaping clinical care, research priorities, and commercial strategies. At the clinical level, earlier genetic diagnosis and phenotype-driven treatment selection are enabling more personalized therapeutic approaches, while the maturation of epilepsy specialty networks is concentrating expertise and improving longitudinal care coordination. Concurrently, advances in pharmacology have diversified the treatment palette, bringing renewed attention to distinct drug classes that target ion channel function, GABAergic modulation, and neuromodulatory pathways.

On the commercial front, digital health tools and telemedicine have expanded care touchpoints and facilitated remote monitoring, thereby altering traditional patterns of utilization across hospitals, specialty centers, and home care. Distribution channel innovation-spanning hospital pharmacies to specialty and online pharmacies-has reconfigured access pathways for high-cost therapies and acute rescue medications. At the same time, regulatory and reimbursement environments are evolving to address the specific needs of rare pediatric disorders, prompting manufacturers to prioritize evidence generation strategies that demonstrate both clinical benefit and real-world impact. Together, these shifts present a new set of opportunities and constraints for stakeholders seeking to advance therapeutic options while ensuring equitable access and sustainable reimbursement.

Understanding the cumulative operational and commercial consequences of evolving United States tariff policies on supply chains, procurement strategies, and access to Dravet syndrome therapies

In 2025, United States tariff dynamics have introduced an additional layer of operational complexity for manufacturers, distributors, and providers engaged in the Dravet syndrome ecosystem. Tariffs that affect imported active pharmaceutical ingredients, certain medical devices, and packaging components have increased upstream input costs and prompted many organizations to re-evaluate supply chain resilience. Firms with global manufacturing footprints have been compelled to assess the total landed cost of goods and to consider options for onshoring or nearshoring critical production steps to mitigate exposure to trade policy volatility.

These supply-side pressures interact with distribution practices in meaningful ways. Specialty pharmacies and hospital procurement groups are adapting contracting strategies to absorb or pass through incremental costs, with implications for inventory management, formulary placement negotiations, and patient out-of-pocket liability. Payers and integrated delivery networks are increasingly scrutinizing cost drivers and may demand enhanced pharmacoeconomic evidence or value-based contracting arrangements to justify coverage of higher-cost therapies. Additionally, tariff-induced changes in component sourcing have accelerated interest in manufacturing partnerships and consolidation among smaller biotechs that lack vertical integration. Overall, the cumulative effect of tariffs is to increase the importance of proactive supply chain planning, transparent cost modeling, and strategic engagement with procurement stakeholders to preserve access and commercial viability.

Deep segmentation-driven insights that synthesize drug class, care setting, distribution pathways, administration routes, and age-group specific clinical imperatives to guide strategy

Segmentation insights reveal differentiated clinical and commercial dynamics across drug classes, end users, distribution channels, routes of administration, and patient age groups. Within drug class segmentation, cannabinoids have garnered sustained interest with therapeutic activity concentrated in cannabidiol and tetrahydrocannabinol subcomponents, while GABA modulators encompass agents such as clobazam, diazepam, and stiripentol that remain central to adjunctive and rescue strategies. Sodium channel blockers, including agents like topiramate and valproate, continue to be relevant for certain seizure phenotypes, and the comparative safety and tolerability profiles of these classes inform prescriber choice and polytherapy strategies.

End user segmentation underscores distinct care delivery pathways: home care settings are increasingly important for long-term maintenance regimens and rescue medication administration, hospitals remain the locus for acute management and complex diagnostics, and specialty epilepsy centers provide concentrated expertise for refractory cases and surgical evaluations. Distribution channel segmentation shapes access modalities and patient experience, as hospital pharmacies, online pharmacies, retail pharmacies, and specialty pharmacies each present different operational and reimbursement interfaces that can affect initiation and continuity of therapy. Route of administration is another critical axis of differentiation; injectable and nasal routes are prioritized for rapid rescue intervention, oral and oromucosal forms support chronic management, and transdermal approaches are being explored for adherence and tolerability benefits. Patient age group segmentation highlights the spectrum of clinical needs across adolescents, adults, children, and infants, with infants and young children requiring tailored dosing, formulation considerations, and heightened safety monitoring. Integrating these segmentation lenses is essential for designing clinical development programs, market access strategies, and patient support services that align with real-world care pathways.

Regionally nuanced clinical and commercial insights that map access realities, regulatory differences, and care infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on clinical practice, regulatory environments, and commercial opportunity for therapies addressing Dravet syndrome. In the Americas, stakeholders benefit from established specialty care networks, advanced genetic diagnostics infrastructure, and evolving payer models that are increasingly receptive to evidence demonstrating meaningful clinical and functional gains. Access challenges persist, however, particularly in rural and under-resourced communities where specialty epilepsy centers are scarce and telehealth adoption varies by payer policy.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and payer systems that require tailored market entry strategies; centralized approvals and national reimbursement negotiations can lead to divergent timelines and formulary outcomes across countries. Countries with strong rare disease programs and coordinated registries show faster uptake of innovative therapies, while others face infrastructure and funding constraints that limit access. Asia-Pacific is characterized by rapid adoption of diagnostic technologies in some markets and variable reimbursement pathways across others. Local manufacturing and procurement policies, as well as differing regulatory expectations for pediatric data, shape clinical adoption and commercial pathways. Across all regions, meaningful engagement with patient advocacy groups, investment in provider education, and alignment with local clinical guidelines remain critical to improving diagnosis, treatment initiation, and long-term management outcomes.

Strategic company landscape analysis highlighting how integrated capabilities across big pharma, biotech innovators, academic centers, and service providers determine competitive positioning

Corporate and institutional activity in the Dravet syndrome ecosystem reflects a mix of established pharmaceutical companies, specialty biotechs, academic centers, contract manufacturing organizations, and specialty pharmacies, each playing complementary roles. Established companies often drive late-stage development and large-scale manufacturing capacity, and they have the commercial infrastructure to support complex payer negotiations and broad distribution networks. Specialty biotechs contribute innovation through targeted mechanisms of action and novel formulations, frequently advancing therapies through earlier-phase trials and leveraging strategic partnerships to scale.

Academic medical centers and epilepsy clinics contribute critical real-world data, investigator-initiated studies, and natural history registries that inform both clinical development and health technology assessment. Contract manufacturing organizations and specialty pharmacies provide operational capabilities to manage orphan and pediatric product demands, including specialized compounding, cold chain logistics, and patient support services. Across this landscape, cross-sector collaboration is increasingly common, combining scientific expertise, clinical credibility, and distribution know-how to accelerate translation from bench to bedside. Companies that can integrate strong clinical evidence generation with sophisticated access strategies and robust patient support programs are positioned to lead in this therapeutic area.

Actionable, high-impact recommendations for product development, supply chain optimization, and payer engagement tailored to the unique demands of Dravet syndrome stakeholders

Industry leaders should pursue a set of pragmatic, evidence-focused actions to convert scientific advances into sustainable patient benefit and commercial success. First, prioritize early and continuous engagement with regulatory authorities and payers to align evidence generation with reimbursement requirements and to design adaptive development plans that accommodate pediatric safety and efficacy endpoints. Second, invest in diagnostic infrastructure and genetic testing partnerships to accelerate accurate early diagnosis, which in turn improves trial recruitment and real-world treatment targeting.

Third, reinforce supply chain resilience by diversifying sourcing of critical inputs, exploring nearshoring for selected manufacturing steps, and formalizing contingency plans to address tariff or trade disruptions. Fourth, develop differentiated distribution strategies that leverage specialty pharmacies for high-touch support, hospital pharmacies for acute care pathways, and online channels to reach geographically dispersed patient populations, with tailored adherence and education programs. Fifth, design age-appropriate formulations and administration routes that reflect the clinical realities of infants, children, adolescents, and adults, thereby enhancing tolerability and adherence. Finally, cultivate partnerships with specialty epilepsy centers and patient advocacy organizations to co-develop registries and real-world evidence initiatives that substantiate long-term outcomes and value, enabling more credible conversations with payers and health systems.

A transparent mixed-methods research methodology integrating clinical evidence review, expert interviews, and case study analysis to produce actionable and validated insights

The research methodology underpinning this analysis combines rigorous evidence synthesis with targeted stakeholder engagement to ensure relevance and credibility. Primary inputs include systematic review of peer-reviewed clinical literature, regulatory guidance documents, and clinical trial registries to capture therapeutic mechanisms, safety profiles, and trial designs. Secondary inputs draw on publicly available policy and payer documentation, technical white papers, and practice guidelines to contextualize access pathways and clinical adoption trends. Expert interviews with neurologists, epileptologists, specialty pharmacists, and health economics specialists were conducted to validate interpretive findings and to surface practical operational considerations not always explicit in the literature.

Qualitative thematic analysis and cross-validation of findings ensured consistency across data sources, while case study reviews of recent therapeutic launches provided real-world illustrations of commercialization challenges and successful strategies. The methodology emphasized transparency, with clear documentation of source types, interviewee roles, and analytical assumptions. Wherever possible, findings were triangulated across multiple sources to bolster reliability. This mixed-methods approach balances depth of clinical insight with practical commercial intelligence, providing stakeholders with actionable knowledge grounded in both evidence and frontline experience.

A forward-looking conclusion that synthesizes clinical progress, operational imperatives, and collaborative strategies necessary to improve care and access for Dravet syndrome patients

In conclusion, addressing the complex clinical and commercial challenges of Dravet syndrome requires coordinated efforts across diagnostic, therapeutic, and access domains. Advances in genetic diagnosis and diversifying therapeutic classes are creating new opportunities to improve seizure control and developmental trajectories, but realizing these benefits hinges on thoughtful evidence strategies, resilient supply chains, and payer-aligned value demonstration. Care delivery shifts toward telehealth and specialty-centric models offer avenues to expand access, yet disparities remain that demand targeted interventions at the regional and local levels.

Stakeholders who integrate precision diagnosis, age-appropriate formulation development, and robust patient support while engaging payers proactively will be best positioned to translate scientific progress into sustained clinical impact. Collaborative models that bring together industry, clinicians, and patient advocates to co-create registries and real-world evidence programs will strengthen the case for coverage and reimbursement. The path forward is pragmatic: combine scientific rigor with operational excellence and stakeholder alignment to deliver meaningful improvements for patients living with Dravet syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of gene therapy pipelines targeting SCN1A mutations in Dravet syndrome patients
  • 5.2. Increasing adoption of cannabidiol-based formulations for adjunctive seizure management in Dravet syndrome
  • 5.3. Rising investments in precision medicine initiatives for pediatric epileptic encephalopathies treatment
  • 5.4. Growing integration of real-world evidence to assess long-term treatment outcomes in Dravet syndrome
  • 5.5. Emergence of novel antisense oligonucleotides tailored to modulate defective sodium channel gene expression
  • 5.6. Development of at-home seizure monitoring devices leveraging AI for real-time intervention in Dravet syndrome
  • 5.7. Collaborations between pharmaceutical and biotech firms to accelerate clinical trials in rare epilepsy disorders

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dravet Syndrome Market, by Drug Class

  • 8.1. Cannabinoids
    • 8.1.1. Cbd
    • 8.1.2. Thc
  • 8.2. Gaba Modulators
    • 8.2.1. Clobazam
    • 8.2.2. Diazepam
    • 8.2.3. Stiripentol
  • 8.3. Sodium Channel Blockers
    • 8.3.1. Topiramate
    • 8.3.2. Valproate

9. Dravet Syndrome Market, by End User

  • 9.1. Home Care
  • 9.2. Hospital
  • 9.3. Specialty Epilepsy Centers

10. Dravet Syndrome Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Pharmacies

11. Dravet Syndrome Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Nasal
  • 11.3. Oral
  • 11.4. Oromucosal
  • 11.5. Transdermal

12. Dravet Syndrome Market, by Patient Age Group

  • 12.1. Adolescents
  • 12.2. Adults
  • 12.3. Children
  • 12.4. Infants

13. Dravet Syndrome Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dravet Syndrome Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dravet Syndrome Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Jazz Pharmaceuticals plc
    • 16.3.2. UCB SA
    • 16.3.3. Marinus Pharmaceuticals, Inc.
    • 16.3.4. Stoke Therapeutics, Inc.
    • 16.3.5. Zogenix, Inc.
    • 16.3.6. Biogen Inc.
    • 16.3.7. Ionis Pharmaceuticals, Inc.
    • 16.3.8. Xenon Pharmaceuticals Inc.
    • 16.3.9. Ovid Therapeutics, Inc.
    • 16.3.10. Zynerba Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2032 (USD MILLION)
  • TABLE 331. ASEAN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 332. ASEAN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 333. ASEAN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 334. ASEAN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 335. ASEAN DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. ASEAN DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 340. ASEAN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 341. ASEAN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-202